95 related articles for article (PubMed ID: 1976871)
1. The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
Weide R; Dowding C; Paulsen W; Goldman J
Leukemia; 1990 Oct; 4(10):695-9. PubMed ID: 1976871
[TBL] [Abstract][Full Text] [Related]
2. [P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia].
Carulli G; Marini A; Caracciolo F
Medicina (Firenze); 1989; 9(4):409-10. PubMed ID: 2576761
[TBL] [Abstract][Full Text] [Related]
3. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Dhingra K; Talpaz M; Kantarjian H; Ku S; Rothberg J; Gutterman JU; Kurzrock R
Leukemia; 1991 Mar; 5(3):191-5. PubMed ID: 2013978
[TBL] [Abstract][Full Text] [Related]
4. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method.
Kuwao F; Takahashi I
Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617
[TBL] [Abstract][Full Text] [Related]
5. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976
[TBL] [Abstract][Full Text] [Related]
8. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
10. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents.
Hait WN; Choudhury S; Srimatkandada S; Murren JR
J Clin Invest; 1993 May; 91(5):2207-15. PubMed ID: 8098047
[TBL] [Abstract][Full Text] [Related]
12. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
13. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
[TBL] [Abstract][Full Text] [Related]
14. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia.
Michelutti A; Michieli M; Damiani D; Melli C; Geromin A; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(3):200-4. PubMed ID: 7926967
[TBL] [Abstract][Full Text] [Related]
16. The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia.
Aumann K; Lassmann S; Schöpflin A; May AM; Wöhrle FU; Zeiser R; Waller CF; Hauschke D; Werner M; Brummer T
Hum Pathol; 2011 May; 42(5):719-26. PubMed ID: 21292300
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
[TBL] [Abstract][Full Text] [Related]
18. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
19. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.
Zheng C; Li L; Haak M; Brors B; Frank O; Giehl M; Fabarius A; Schatz M; Weisser A; Lorentz C; Gretz N; Hehlmann R; Hochhaus A; Seifarth W
Leukemia; 2006 Jun; 20(6):1028-34. PubMed ID: 16617318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
